PureTech Health Advances Deupirfenidone for IPF with FDA Support

PureTech Health ( (GB:PRTC) ) has provided an update.

PureTech Health announced a successful End-of-Phase 2 meeting with the FDA for deupirfenidone (LYT-100), a potential new standard of care for idiopathic pulmonary fibrosis (IPF). The FDA’s feedback supports the advancement into a pivotal Phase 3 trial, set to begin in early 2026, which will compare deupirfenidone to pirfenidone. This trial aims to confirm the drug’s efficacy and safety, potentially leading to its registration via a streamlined regulatory pathway. If successful, this development could significantly impact the treatment landscape for IPF, offering a more effective and tolerable option for patients.

The most recent analyst rating on (GB:PRTC) stock is a Hold with a £125.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.

Spark’s Take on GB:PRTC Stock

According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.

PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.

To see Spark’s full report on GB:PRTC stock, click here.

More about PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value through a capital-efficient R&D model. The company has produced several therapeutic candidates, including three that have received U.S. FDA approval, and operates by creating Founded Entities like Celea Therapeutics to advance promising medicines.

Average Trading Volume: 751,977

Technical Sentiment Signal: Strong Sell

Current Market Cap: £294.9M

For a thorough assessment of PRTC stock, go to TipRanks’ Stock Analysis page.